CLINICAL OUTCOMES WITH FIRST-LINE BEVACIZUMAB AND CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER AND A HISTORY OF DIABETES: RESULTS FROM THE ARIES OBSERVATIONAL COHORT STUDY

被引：1
|
作者：
Bendell, J. [1 ]
Cohn, A. [2 ]
Mun, Y. [3 ]
Fish, S. [3 ]
Sommer, N. [3 ]
Grothey, A. [4 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Mayo Clin, Coll Med, Div Med Oncol, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu164.10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 0010
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
  • [22] Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).
    Hedrick, E.
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Sugrue, M.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 155S - 155S
  • [23] Serious bleeding events are uncommon in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen. results from the brite observational cohort study
    Kozloff, M.
    Sugrue, M.
    Chiruvolu, P.
    Feng, S.
    Purdie, D.
    Grothey, A.
    Sargent, D.
    Berlin, J.
    Kabbinavar, F.
    Dong, W.
    Flynn, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [24] First-line bevacizumab (REV) and chemotherapy (CT) for metastatic colorectal cancer (mCRC); Results from a developing nation
    Franke, F. A.
    Azevedo, S. J.
    Gampel, O.
    Guimaraes, J. Q.
    Schaum, M. R.
    Murad, A.
    Coutinho, A. K.
    Oliveira, J. A.
    Matos Neto, J. N.
    Franca, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS)
    Bekaii-Saab, T. S.
    Bendell, J. C.
    Cohn, A. L.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Tezcan, H.
    Feng, S.
    Sing, A.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort
    Annie Fourrier-Réglat
    Denis Smith
    Magali Rouyer
    Jacques Bénichou
    Rosine Guimbaud
    Yves Bécouarn
    Olivier Bernard
    Pernelle Noize
    Nicholas Moore
    Alain Ravaud
    Targeted Oncology, 2014, 9 : 311 - 319
  • [27] Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort
    Fourrier-Reglat, Annie
    Smith, Denis
    Rouyer, Magali
    Benichou, Jacques
    Guimbaud, Rosine
    Becouarn, Yves
    Bernard, Olivier
    Noize, Pernelle
    Moore, Nicholas
    Ravaud, Alain
    TARGETED ONCOLOGY, 2014, 9 (04) : 311 - 319
  • [28] A Japanese cohort study of first-line chemotherapy for metastatic colorectal cancer: The EMERaLD study
    Takeda, K.
    Amano, T.
    Ohashi, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S358 - S358
  • [29] IMPROVED CLINICAL OUTCOMES IN METASTATIC COLORECTAL CANCER PATIENTS ON FIRST-LINE CHEMOTHERAPY WITH BEVACIZUMAB CAN BE PREDICTED BY EARLY RISE IN BLOOD PRESSURE
    Upanal, N.
    Ackland, S.
    Bonaventura, A.
    McElduff, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 58 - 59
  • [30] Safety and efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRITE)
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Steis, R.
    Dong, W.
    Suzuki, S.
    Sugrue, M.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 128 - 128
12345